BioSpace News Archive

RespireRx Pharmaceuticals Inc. is pleased to announce that, on November 14, 2022, the Company entered into a letter of intent with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic clinical research.

Millstone Medical Outsourcing, the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces its completed acquisition of MycoScience, on November 14, 2022.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company’s next-generation Advanced Circulatory Support (ACS) pump and controller system.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the “Units”) at a price of $1,000 per Unit for aggregate gross proceeds of $2,355,000 (the “Offering”).

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.

Emmaus Life Sciences, Inc. announced that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari® in the country.

The global MicoRNA (miRNA) Market was valued at USD 190.6 Million in 2020 and is expected to reach USD 458.0 Million by 2030, at a CAGR of 11.6%.

The global Cancer Stem Cell Therapeutics Market was valued at USD 10.15 Billion in 2020 and is expected to reach USD 20.08 Billion by 2030, at a CAGR of 9.0%.

The global mastocytosis market registered a steady growth during 2021 and is expected to grow at a higher revenue CAGR over the forecast period.

The Global 3D Cell Culture Market is projected to grow at a CAGR of 15.8% from USD 1,032.9 Million in 2020 to USD 3,319.43 Million in 2030.